Kornimate/medical-research-clean huggingface dataset:
microbiome, antibiotics, and growth infant cohort

Conditions: Obesity, Childhood; Antibiotic Side Effect

Summary: this cross-disciplinary study will assemble and longitudinally follow a large, diverse birth cohort to determine the relationships between early life antibiotic exposure, microbiome development, growth, antibodies, and immunostimulation.

perinatal and infant antibiotic exposures are common and have been linked to changes in the gut microbiome, which plays a central role in health and disease. childhood obesity is an epidemic and animal models have linked antibiotic induced changes in the microbiome with increased adiposity. infants become colonized with trillions of bacteria in the first few hours of life. during this time period, their nascent immune system develops tolerance to commensal microbes the primary objectives are to measure the impact of common perinatal and early childhood antibiotic exposures on the structure and function of the developing gut microbiome. to determine the association between common perinatal and early childhood antibiotic exposures and weight/adiposity gain in a large birth cohort of children. to determine mechanisms for the association between microbiome changes over time and the rate of weight/adiposity gain in a large birth cohort of children. to determine the normal developmental pattern by which healthy children develop antibodies in their blood against the microbes that naturally colonize their intestines. to determine the association between immunostimulation and protection from persistent colonization in humans.

Eligibility criteria:
inclusion criteria (if not specified, applies to child): * born at pennsylvania hospital * recruited at \<120 hours of age * born at ≥36 0/7 weeks gestation * birth weight ≥2000 grams * parents plan to receive well-child care in the children's hospital of philadelphia (chop) network, society hill pediatrics, center city pediatrics, penn medicine or south philly pediatrics * biological mother is the legal guardian, or the child is born from a surrogacy with guardianship immediately transferred in hospital exclusion criteria (if not specified, applies to child): * child in neonatal intensive care unit (nicu) for \>120 cumulative hours * biological mother not legal guardian, except surrogacy where guardianship is transferred at birth * biological mother not primary caretaker, except surrogacy where guardianship is transferred at birth * biological mother \< 18 years of age * child has culture confirmed (blood or cerebrospinal fluid cultures) infection * biological mother is non-english speaking

Keywords: microbiome antibiotics growth
validity of elastography during pregnancy

Conditions: Hepatitis B Virus Infection; Pregnant Women

Summary: non invasive methods are the only available methods to stage liver fibrosis during pregnancy. the safety of elastometry - ultrasound based - is obvious, as medical supervision of pregnancy is based on ultrasonography, both methods using same wavelengths. therefore, this method is sometimes used in pregnant women with recent diagnosis of chronic viral hepatitis infection, whereas its validity in pregnant women has never been studied. this lack of data justifies our study.

one measurement during the third trimester of pregnancy will be compared to a second measurement, 3 months after childbirth.

Eligibility criteria:
inclusion criteria: * pregnant women * followed in obstetrics dpt * hbv or hcv chronic hepatitis * after information and written consent exclusion criteria: * none
evaluation of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma

Conditions: Glioblastoma, IDH-wildtype; Glioblastoma; Glioblastoma Multiforme; Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype; GBM

Summary: the purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

this open label dose escalation and expansion study will be conducted using a standard dose-escalation design with escalating doses of eflornithine plus temozolomide at the approved dose level, followed by an expansion cohort that will further evaluate safety and preliminary efficacy of the combination at the recommended phase 2 dose. duration of participation will be up to 56 weeks in total per patient: screening period - a maximum screening duration of 4 weeks. treatment period - up to 48 weeks. follow-up visit - 4 weeks from last treatment. a total of up to 66 patients will be enrolled in a non-randomized fashion (patients may be added to any of the dose levels below the rp2d to a maximum of approximately 20 per dose level with the intent of further characterizing safety and pharmacokinetics).

Eligibility criteria:
inclusion criteria: * diagnosis of world health organization (who) g4 classified gbm, idh-wildtype per who 2021 tumor classification. * completed external beam radiation therapy per standard of care. * must have received at least 80% of planned daily doses of tmz during chemoradiation. * adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing. * willing to abstain from intercourse or use acceptable contraceptive methods. * if taking corticosteroids, must be on a stable or decreasing dose. exclusion criteria: * recent history of recurrent or metastatic cancer that could confound response assessments * prior systemic chemotherapy for gbm other than temozolomide during external beam radiation therapy. * prior optune treatment. * active infection or serious intercurrent medical illness. * poorly controlled seizures. * significant cardiac disease within 6 months of enrollment. * poorly controlled diabetes. * use of another investigational agent within 30 days of enrollment.
electronic media and its application in psychotherapy

Conditions: Anxiety Disorders; Depression; Electronic Media

Summary: this randomized control trial aims to establish whether viewing and discussing patients' electronic communication (texts, emails, facebook direct messaging, etc) impacts clinical care and decision making across the lifespan.

this study explores the usefulness and effectiveness of including electronic communication as part of standard clinical care. participants will provide information and content from their electronic media to research assistants during in person interviews if they are in the intervention group. research assistants will then give clinicians the information collected, so the clinicians can incorporate the data into the session as they see fit. therapists will retain full clinical discretion of how they continue to conduct their therapy sessions. the investigators will compare the impact of receiving this electronic enhancement intervention versus only receiving treatment as usual care on mental health related functioning and therapeutic alliance.

Eligibility criteria:
inclusion criteria: 1. are currently receiving psychotherapy at mclean and have had at least 4 visits with their current therapy provider in outpatient clinics or 2 sessions with their therapy provider in partial hospitalization or residential settings 2. age 18-85, and fluent in english 3. have a primary diagnosis of anxiety or depression (as determined by self-report and review of medical records, which should list a primary depression or anxiety spectrum diagnosis). symptomatology can be active or in remission. 4. are actively using at least 1 platform for text messaging (i.e. they should have an account on each platform and have produced content within the month prior to beginning the study). this will be based on self report. 5. use a mobile device for text messaging 6. able to provide informed consent. exclusion criteria: 1. probable or diagnosed dementia or cognitive impairment, or neurodevelopmental disorder (such as an autism spectrum disorder) based on self report and review of medical records. - individuals with attention-deficit/hyperactivity disorder (adhd) or attention-deficit disorder (add) may be eligible provided symptoms have been stable for at least 6 months. 2. active psychotic symptoms - history of psychosis is allowable only if the patient has not had symptoms for at least a year 3. are actively receiving ect treatment 4. current alcohol or drug abuse problem (based on self report and review of medical records) - history of substance use is fine, provided there has been no relapse or withdrawal symptoms in the month leading up to enrollment 5. are involuntarily admitted to mclean hospital
metronomic capecitabine in stage iii gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage iii who had received standard treatment.


Eligibility criteria:
inclusion criteria: 1. lower age limit of research subjects 18 years old and upper age limit of 80 years old. 2. be proven to be primary adenocarcinoma of gastric cancer and staged iii by pathological evidences 3. r0 gastrectomy with d2 lymphadenectomy 4. ecog (ecog score standard) performance status of 0 or 1 and expected to survive more than 6 months 5. no contraindications, including normal peripheral blood routine, liver and kidney function and electrocardiogram （wbc≥3.5 x 109 /l, neu≥1.2 x 109 /l,plt≥90 x 109 /l and hgb≥80g/l). exclusion criteria: 1. history of chemotherapy, radiotherapy, immunotherapy or target therapy 2. multiple primary tumors 3. suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases 4. unavailable for r0 resection and d2 lymph node dissection. 5. patients with stage iv gastric cancer

Keywords: gastric cancer metronomic capecitabine
use of continuous glucose monitors in publicly-insured youth with type 2 diabetes - a pilot and feasibility study

Conditions: Type 2 Diabetes

Summary: the purpose of this pilot feasibility study is to provide continued cgm access to youth with type 2 diabetes and collect descriptive data about feasibility of use of cgm in youth with type 2 diabetes ages 4 years and older. from this study the investigators hope to learn if cgm use in youth with type 2 diabetes can be tolerated and sustained with good adherence and to describe blood glucose patterns in youth with type 2 diabetes. the primary aim will be to evaluate the feasibility of cgm start and continuation in youth with t2d and describe glucose metrics and patient reported outcomes (pros). the investigators will pilot and refine a program to test the hypothesis that cgm start and continuation in youth with t2d is feasible and then evaluate glucose metrics and pros.


Eligibility criteria:
inclusion criteria: * public insurance * between ages 4-19.99 years inclusive * diagnosis of t2d (diabetes autoantibody negative) followed in the pediatric endocrinology clinic at stanford children's health * hba1c greater than 6.5% at enrollment * interested in starting on a continuous glucose monitor * have access to a mobile device that is compatible with cgm applications or willing to use cgm receiver provided exclusion criteria: * non-t2d diagnosis * hga1c \< 6.5% * are not willing to wear cgm * have private health insurance.
gabapentin - a solution to uremic pruritus?

Conditions: Pruritus; Uremia

Summary: to investigate using the drug gabapentin to relieve the intense pruritic sensation associated with chronic renal failure patients undergoing peritoneal dialysis.


Eligibility criteria:
inclusion criteria: * adult chinese male and female patients aged \> 18 undergoing capd for at least 3 months and able to read and understand chinese * patients experiencing moderate to severe pruritis, defined as persistent, treatment-resistant pruritis considerably impairing sleep or daytime activity. treatment resistance is defined as no or only partial resolvement of pruritis under current anti-pruritis treatment regimens such as anti-pruritis lotions and anti-histamines. * patients in stable clinical condition in terms of peritoneal dialysis and general health * patients able to understand and answer the sds questionnaire * patients able to express the sensation of itchiness in the terms of the vas and the sds score * patients who are willing to give written informed consent and to participate in and comply with the study protocol exclusion criteria: * patients with a known history of pruritis or dermatologic disease antedating renal failure. * patients with skin disease other than the usual cutaneous findings of uraemia such as xerosis or ecchymosis. * patients under current treatment with systemic steroids * known history of allergy to gabapentin * those patients already put on anti-convulsants * unable to give written informed consent for the study * pregnancy or female patients of child-bearing age who are unwilling to use contraception * poor drug compliance * known hiv positivity * active neoplastic disease * those who do not want to participate the study

Keywords: uremic pruritis
a clinical study to assess efficacy and safety of aliskiren in the elderly with high blood pressure

Conditions: Hypertension

Summary: after a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks


Eligibility criteria:
inclusion criteria * patients with at least 65 years-old * patients with essential hypertension exclusion criteria * severe hypertension * history or evidence of a secondary form of hypertension * history of hypertensive encephalopathy or cerebrovascular accident. other protocol-defined inclusion exclusion criteria also apply.

Keywords: hypertension aliskiren age
>the purpose of this study was to determine whether consuming a 100-ml cup of coffee is effective in preventing or reducing postoperative ileus after laparotomy of benign gynecological patients

Conditions: Effects of Coffee Ingestion on Recovery of Bowel Function

Summary: comparison of the effectiveness coffee (with or without caffeine) ingestion and water for reducing the duration of postoperative ileus after laparotomy of benign gynecological patients

laparotomy benign gynecological surgery is the most common gynecologic operation worldwide because is major operation for surgery and can affect to bowel movement after operation and turn to postoperative ileus , clinically severe postoperative ileus affects up to 14% of patients after laparotomy for gynecologic surgery that leaded to more complication, slowly recovery , prolong length of hospitalized stay and consequently increase unnecessary cost of treatment. preclinical studies has considered to use preventative therapeutic options for prevent ileus including coffee the investigators used the coffee reduces postoperative ileus however, no good quality of evidence base supports the effectiveness coffee (with or without caffeine) ingestion and water for reducing the duration of postoperative ileus after laparotomy of benign gynecological patients

Eligibility criteria:
inclusion criteria: * patients were asked to participate if they were scheduled to undergo laparotomy for a benign gynecologic condition * ever drink coffee before * can speak or communication thai language exclusion criteria: 1 hypersensitivity or allergy to caffeine/ coffee 2.ever intraabdominal sugery before 3. had an active intra-abdominal malignancy, bowel perforation, pre-existing bowel disease, or a history of abdominal or pelvic irradiation. 4.pregnancy woman 5.thyroid disease 6 inflammatory bowel disease 7.liver disease 8.cardiac arrhythmia 9.history of difficult to defecation ( feces only 2 times per week) 10.after operation need to stay in icu more than 24 hr 11.need to put ng tube after operation

Keywords: benign gynecologic operation coffee ingestion recovery of bowel function
passive music intervention for the reduction of anxiety in patients undergoing bone marrow aspiration and/or biopsy

Conditions: Hematopoietic and Lymphoid System Neoplasm

Summary: this phase iii trial compares the effect of adding passive music when undergoing bone marrow biopsy/aspirate versus bone marrow biopsy/aspirate alone in reducing anxiety. music therapy helps relieve pain or stress and promote well-being. listening to music during a bone marrow biopsy/aspirate procedure may reduce anxiety during the procedure.

primary objective: i. to determine whether music listening alleviates psychological distress such as anxiety in patients undergoing bone marrow aspiration and/or biopsy that do not require general anesthesia. secondary objective: i. to determine if patients with lower to no anxiety during bone marrow aspiration and/or biopsy will also experience less pain. exploratory objective: i. to design and implement an evidence-based music intervention protocol that could be used during bone marrow aspiration and/or biopsy. outline: patients are randomized to 1 of 2 groups. group i: patients undergo standard of care bone marrow biopsy and/or aspiration. group ii: patients listen to music while undergoing standard of care bone marrow biopsy and/or aspiration.

Eligibility criteria:
inclusion criteria: * documented informed consent of the participant and/or legally authorized representative * willingness to participate in the study * ability to read english, or willingness to have one of the staff members help with the questionnaire * age: ≥ 18 years * hematological conditions requiring a bone marrow biopsy and/or aspiration procedure, regardless of their disease state, and experience with such procedures exclusion criteria: * hearing impairments, and non-verbal communication * scheduled to undergo a sedated bone marrow biopsy * scheduled to be premedicated with any anxiolytic or pain medication 30 minutes prior to the procedure * unwillingness to listen to music * altered mental health status that would prohibit informed consent and following protocol required instructions * prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
high interval versus moderate intensity continuous training on soluble st2 biomarkers in chronic heart failure

Conditions: Heart Failure

Summary: this study was designed to compare between the effect of high intensity interval training (hiit) and moderate intensity continuous training (mict) on soluble st2 biomarkers among chronic heart failure patients, also measure the improvement in the quality of life with different modes of exercise and with of it is more benifitial for the heart failure patient

the data concerned with the study including soluble st2 biomarker levels, ejection fraction and mlhfq was measured before and after twelve weeks of treatment.in this study a total sixty male patients with chronic heart failure nyha class (i \&ii) were selected from the outpatient clinic, el-demerdash hospital, ain-shams university. their age ranged from 50-60 years. patients were randomly assigned into two groups, group a receiving hiit along with prescribed medical treatment and group b receiving mct along with prescribed medical treatment.

Eligibility criteria:
inclusion criteria: * the patients selection was according to the following criteria: * patients diagnosed with chronic heart failure (new york heart association class i\& ii) with systolic left ventricular dysfunction. * their left ventricular ejection fraction (lvef) \<40%. * medical treatment was optimized at least three months prior to study entry. * all patients didn't participate in any rehabilitation programs prior to the study. exclusion criteria: * patients who had met one of the following criteria were excluded from the study: 1. signs of acute heart failure, unstable angina or severe arrhythmia three months prior to enrolment in the study. 2. pacemakers. 3. chronic obstructive pulmonary disease. 4. other disorders counteracting exercise testing conditions that limit lower limb mobility (for example, burns, fractures) 5. pre-existing neuromuscular diseases (for example myasthenia gravis).

Keywords: sst2 biomarker minnesota questionare hiits
bilateral prefrontal modulation in crack-cocaine addiction

Conditions: Drug Addiction; Executive Dysfunction

Summary: in this study, eligible crack-cocaine addicted inpatients recruited from specialized clinics for substance abuse disorder treatment, filling inclusion criteria and not showing any exclusion criteria, were randomized to receive the repetitive (10 sessions, every other day) bilateral dorsolateral prefrontal cortex (dlpfc: cathodal left / anodal right) tdcs (2 milliamperes, 3x7 cm2, for 20 min) or placebo (sham-tdcs). craving to the use of crack-cocaine was examined before (baseline), during and after the end of the tdcs treatment. based in our previous data, our hypothesis was that repetitive bilateral tdcs over dlpfc would favorably change clinical, cognitive and brain function in crack-cocaine addiction and these would be long-lasting effects.

before (baseline) and after tdcs or sham-tdcs treatment, subjects were examined: (1) clinically, regarding craving (obsessive compulsive scale) and relapses to the drug use. they were followed-up for clinical examination at least 60 days after treatment.

Eligibility criteria:
inclusion criteria: * patients between the age of 18 and 60 years; * met criteria for crack-cocaine dependence according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5), as determined by clinical evaluation; * in stable clinical condition with no need for inpatient care; * able to read, write, and speak portuguese; and * no severe withdrawal signs or symptoms at baseline. exclusion criteria: * a condition of intoxication or withdrawal due to a substance other than crack-cocaine; * unstable mental or medical disorder or substance abuse or addiction other than crack-cocaine dependence, except nicotine and/or caffeine; * a diagnosis of epilepsy, convulsions; * a previous history of drug hypersensitivity or adverse reactions to diazepam or other benzodiazepines and haloperidol; * any contraindication for electrical brain stimulation procedures such as electronic implants or metal implants; * suspected pregnancy for female participants;

Keywords: crack-cocaine addiction tdcs dlpfc craving cognition
the incidence of necrotizing enterocolitis in preterm with respiratory distress syndrome undergoing caffeine therapy

Conditions: Pharmacological Action of Drug

Summary: it is a randomized, prospective study; it will be carried out in the nicu at alzahraa university hospital including 50 newborn babies diagnosed with respiratory distress syndrome. the purpose of this study is to : 1. investigate the protective caffeine on necrotizing enterocolitis in respiratory distress syndrome preterm infants. 2. detect the impact of caffeine protocol treatment on the in-incidence of necrotizing enterocolitis in respiratory distress syndrome preterm infants in neonatal intensive care 1- control group it includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks. 2- caffeine-treated group it includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.


Eligibility criteria:
inclusion criteria: * all preterm infants with respiratory distress syndrome. exclusion criteria: * preterm admitted to nicu for other reasons rather than respiratory distress * major congenital anomalies * spontaneous intestinal perforation * endocrinal dysfunctions